Rénibus Therapeutics
Bob Schnitzius has over 40 years of professional experience in financial roles. Bob began their career in 1978 as Treasurer at Texas Testing Laboratories. Bob then moved to Shoreline Products in 1983 as Controller/Accounting Manager. In 1991, they joined Medeva PLC (now UCB) as Corporate Controller/Director of Finance/Controller. In 1997, they became Acting President and CEO/CFO at DelSite. In 2009, they became Chief Financial Officer at Life Warmer. In 2010, they were Chief Financial Officer at Behavioral Health Group. In 2013, they were Vice President Finance at ZS Pharma, Inc. In 2017, they started their own consulting business, Schnitzius Consulting, as Principal. Since 2021, they have been Financial Controller and Chief Financial Officer at Rénibus Therapeutics Inc.
Bob Schnitzius obtained a Bachelor of Business Administration (BBA) degree in Accounting from the University of Texas at Arlington - College of Business. Bob also holds a Certified Public Accountant certification from the Texas State Board of Public Accountancy.
This person is not in any offices
Rénibus Therapeutics
Rénibus Therapeutics is a biotech company dedicated to transforming the cardio-renal disease treatment paradigm by focusing on the prevention, treatment, and diagnostic testing of kidney disease.